NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve the management of hepatocellular cancer and metastatic castration-resistant prostate cancer (mCRPC). After hearing and assimilating this program, the clinician will be better able to:
1. Identify patients with intermediate or advanced hepatocellular cancer who are candidates for systemic therapy.
2. Choose effective therapeutic agents for patients with hepatocellular cancer.
3. Compare and contrast real world and clinical trial data on patients with mCRPC.
4. Determine the optimal sequencing of therapies for mCRPC with the help of genomic profiling.
5. Use clinical characteristics to develop an appropriate sequencing plan for the management of mCRPC.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2022-07-15 05:00:00
- End Date: 2022-07-15 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all